Aardvark Therapeutics Stock
Aardvark Therapeutics, Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Tien-Li Lee
- Employees
- 28
- Market cap
- $83 M
- IPO
- 13/02/2025
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary…
Aardvark Therapeutics stock: price history
1D
-2.1%
1W
-20.6%
1M
-26.6%
6M
-27.7%
YTD
-71.2%
1Y
-71.6%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~16% weaker price swings than usual
Ask the agents about Aardvark Therapeutics
Analyst assessment of Aardvark Therapeutics
PRICE TARGET LOW
US$3.00
CONSENSUS
US$3.00
MEDIAN
US$3.00
PRICE TARGET HIGH
US$3.00
0
STRONG BUY
4
BUY
4
HOLD
1
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 24/09/2026
Aardvark Therapeutics stock metrics
P/E
-1.18
P/B
1.1
EV/EBITDA
-0.14
RETURN ON EQUITY
-19.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
50.3%
FLOAT SHARES
11,008,078
AVG. DAILY VOLUME (30D)
136,253
Insider transactions (SEC)
Sun Nelson
Sun Nelson
Institutional holders
Comparable stocks
Frequently asked questions about Aardvark Therapeutics stock
What does Aardvark Therapeutics do?
Aardvark Therapeutics, Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Tien-Li Lee, the company employs around 28 people.
The IPO was on 13/02/2025; the stock trades on NASDAQ under the ticker AARD.
What do analysts say about Aardvark Therapeutics stock?
9 analysts rate the stock, the consensus is Buy (as of 24/09/2026).
The average price target is US$3.00, ranging from US$3.00 to US$3.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
When does Aardvark Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -16% stronger than usual.
Does Aardvark Therapeutics pay a dividend?
No, Aardvark Therapeutics currently does not pay a dividend.
Which stocks are comparable to Aardvark Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Aardvark Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Aardvark Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.